VVOS — Vivos Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $8.48m
- $15.38m
- $17.44m
Annual cashflow statement for Vivos Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -20.3 | -23.8 | -13.6 | -11.1 | -21.2 |
| Depreciation | |||||
| Non-Cash Items | 3.79 | 1.88 | -1.85 | 0.804 | 0.661 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.028 | 1.71 | 2.86 | -2.94 | 4 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -15.7 | -19.6 | -11.9 | -12.7 | -15.3 |
| Capital Expenditures | -2.4 | -0.924 | -0.803 | -0.568 | -2.34 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0.212 | 0 | -0.05 | 0 | -5.18 |
| Acquisition of Business | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -2.61 | -0.924 | -0.853 | -0.568 | -7.53 |
| Financing Cash Flow Items | -2.24 | 0 | -1.08 | -1.36 | -0.837 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 24.2 | 0 | 10.9 | 17.9 | 18.6 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 5.82 | -20.5 | -1.88 | 4.62 | -4.23 |